LDCT Lung Screening for Early Detection of Lung Cancer
Trial Summary
What is the purpose of this trial?
Low-dose CT Screening has been shown in two large trials in the United States (NLST) and Europe (NELSON) to increase overall survival in subjects 55 years of age and older with a strong smoking history. Unfortunately, in both North Carolina (NC) and South Carolina (SC), subjects are found to have the above referenced smoking history prior to reaching the minimum age in these studies. This study is aimed at decreasing the minimum age of screening in a high-risk population.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Mobile Low-dose Computed Tomography (LDCT) Screening for early detection of lung cancer?
Is low-dose computed tomography (LDCT) screening safe for humans?
How is Mobile Low-dose Computed Tomography (LDCT) Screening different from other treatments for lung cancer?
Mobile Low-dose Computed Tomography (LDCT) Screening is unique because it is a non-invasive imaging technique used to detect lung cancer early in high-risk individuals, such as smokers, by using lower doses of radiation compared to standard CT scans. Unlike treatments that address existing cancer, LDCT is used for early detection, which can significantly reduce lung cancer mortality by identifying cancer at a stage when it is more treatable.59111213
Research Team
Daniel Carrizosa, MD
Principal Investigator
LCI
Eligibility Criteria
This trial is for people aged 40-54 who have a significant smoking history (at least 30 pack years), are currently smoking or quit within the last 15 years, and can understand English/Spanish. They must consent to share health information and follow study procedures. Those with past lung cancer diagnosis, CT scan contraindications, or pregnancy cannot join.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Initial Screening (T0)
Participants undergo their first mobile low-dose CT screening to evaluate lung cancer diagnosis rate
Subsequent Screenings (T1 and T2)
Participants undergo subsequent mobile low-dose CT screenings to evaluate lung cancer diagnosis rate and positive screening rate
Follow-up
Participants are monitored for safety and effectiveness after screenings
Treatment Details
Interventions
- Mobile Low-dose Computed Tomography (LDCT) Screening (Procedure)
Mobile Low-dose Computed Tomography (LDCT) Screening is already approved in Canada for the following indications:
- Lung cancer screening for high-risk populations aged 55 and older
Find a Clinic Near You
Who Is Running the Clinical Trial?
Daniel Carrizosa
Lead Sponsor
Wake Forest University Health Sciences
Lead Sponsor
Leon Levine Foundation
Collaborator